Molecules in focus

Phosphorylation mediated structural and functional changes in pentameric ligand-gated ion channels: Implications for drug discovery

Sahil Talwar [a], Joseph W. Lynch [a,b,∗]

[a] Queensland Brain Institute, The University of Queensland, St Lucia 4072, Australia
[b] School of Biomedical Sciences, The University of Queensland, St Lucia 4072, Australia

ABSTRACT

Pentameric ligand-gated ion channels (pLGICs) mediate numerous physiological processes, including fast neurotransmission in the brain. They are targeted by a large number of clinically-important drugs and disruptions to their function are associated with many neurological disorders. The phosphorylation of pLGICs can result in a wide range of functional consequences. Indeed, many neurological disorders result from pLGIC phosphorylation. For example, chronic pain is caused by the protein kinase A-mediated phosphorylation of $\alpha 3$ glycine receptors and nicotine addiction is mediated by the phosphorylation of $\alpha 4$- or $\alpha 7$-containing nicotinic receptors. A recent study demonstrated that phosphorylation can induce a global conformational change in a pLGIC that propagates to the neurotransmitter-binding site. Here we present evidence that phosphorylation-induced global conformational changes may be a universal phenomenon in pLGICs. This raises the possibility of designing drugs to specifically treat disease-modified pLGICs. This review summarizes some of the opportunities available in this area.

© 2014 Elsevier Ltd. All rights reserved.

1. Introduction

The pentameric ligand-gated ion channel (pLGIC) family includes nicotinic acetylcholine receptors (nAChRs), GABA_A receptors (GABA_ARs), glycine receptors (GlyRs) and 5-HT_3 receptors (5-HT_3Rs). Although these receptors are involved in many physiological processes, they are probably best known for mediating fast neurotransmission in the nervous system. They have been implicated in numerous channelopathies with neurological manifestations and are pivotal pharmacological targets. For example, nAChRs play a clinical role in nicotine addiction and are therapeutic targets for Alzheimer's disease and schizophrenia (Pollock et al., 2009); GABA_ARs are important clinical targets for epilepsy (Abramian et al., 2010), anxiety, addiction and anaesthesia (Song and Messing, 2005); GlyRs are emerging targets for chronic inflammatory pain (Harvey et al., 2004).

Phosphorylation is well known to influence synaptic function by directly modulating pLGICs (Swope et al., 1999). Indeed, pLGIC phosphorylation has been implicated in various disorders such as nicotine addiction (Wecker et al., 2001), status epilepticus (Terunuma et al., 2008) and chronic pain (Harvey et al., 2004). Phosphorylation of pLGICs can elicit a wide variety of effects, ranging from alterations in the level of surface expression, synaptic targeting and receptor desensitization. Many of these effects are summarized in Table 1. Until recently, there have been few attempts to resolve the structural basis of these effects. By doing so, it may be possible to design drugs to specifically treat the consequences of pathological receptor modifications that lead to disease. This review summarizes some of the opportunities available in this area.

2. Structure

2.1. pLGIC architecture

Functional pLGICs comprise pentameric assemblies of identical or different subunits (Fig. 1A). The five subunits together form a central water-filled pore that facilitates transmembrane ion flux (Fig. 1B). Each subunit can be divided into three domains, an extracellular ligand-binding domain, four transmembrane helices (termed M1–M4) and a large intracellular M3–M4 domain which

Table 1
Effect of phosphorylation on pLGICs and their relevance to diseases.

Receptor	Subtype	Phosphorylation site	Protein kinase	Effect on receptor function	Disease relevance	References
GlyR	α3	S346	PKA	Inhibition of glycinergic currents	Chronic inflammatory pain	Harvey et al. (2004)
	β1	S409	PKA, PKC	Enhanced desensitization and prolonged deactivation	Epilepsy	Hinkle and Macdonald (2003)
	β3	S408, S409	PKC	Alterations in cell surface expression.	Status epilepticus	Terunuma et al. (2008)
			PKC	BDNF-mediated transient increase in receptor function followed by down regulation	Neuronal Excitotoxicity	Jovanovic et al. (2004)
		S383	CamKII	Rapid insertion of extrasynaptic receptors at the cell surface and enhanced tonic currents in hippocampus	Neuropsychiatric disorders	Saliba et al. (2012)
GABA$_A$R	γ2	S327	PKC	Alterations in ethanol and benzodiazepine sensitivity	Alcoholism	Qi et al. (2007)
		S343	PKC	Increased amplitude of mIPSCs	Alcoholism	Song and Messing (2005)
		Y365, Y367	Src	Increased postsynaptic receptor expression and enhanced frequency of hippocampal mIPSCs	Spatial memory deficits	Tretter et al. (2009), Luscher et al. (2011)
	α4	S443	PKC	Increased cell surface stability and activity	Temporal lobe epilepsy	Abramian et al. (2010)
	α7	Y386, Y442	Src	Increased current amplitudes with no change in surface receptor number	Cognition and addiction	Charpantier et al. (2005)
		Y386, Y442, Y317	Src	Increased surface receptor numbers with no change in open probability		Cho et al. (2005)
nAChR (neuronal)	α4	S368	PKC	Prolonged nicotine-induced desensitization	Nicotine addiction	Wecker et al. (2001)
		S365, S472, S491	PKA	Increased surface expression		Guo and Wecker (2002)
		S467	PKA	Favoured expression of low-affinity receptors		Bermudez and Moroni (2006), Pollock et al. (2009)
		S550	PKC	Dual action affecting mature receptors to stabilize the receptors at cell surface and increase transport of immature receptors from endoplasmic reticulum to membrane		Pollock et al. (2009)
	β	Y390	Src	Decreased receptor turnover and metabolic stabilisation	Myasthenia gravis	Rudell and Ferns (2013)
		Y355	Src	Enhanced desensitization and immobilization of the receptor		Tzartos et al. (1993)
nAChR (muscle)	δ	S361, S362	PKA	Enhanced desensitization	Myasthenia gravis	Hoffman et al. (1994)
		Y372	Src	Stable localisation of the receptor during synaptogenesis		Wagner et al. (1991)
	γ	S353, S354	PKA	Enhanced desensitization		Hoffman et al. (1994)

has a length and primary structure that varies enormously among pLGIC members (Fig. 1A). The extracellular domain predominantly comprises a twisted β-sheet sandwich with ligand-binding pockets located at the subunit interfaces. The principal (+) side of the pocket is lined by binding domain loops A, B and C and the complementary (−) side is lined by binding loops D, E and F (Fig. 1A). The transmembrane α-helices form concentric rings around a central ion pore, which is directly lined by five M2 helices (Fig. 1A).

2.2. Structure and importance of the M3–M4 cytoplasmic domain

Unlike the extracellular and transmembrane domains, the M3–M4 domain is poorly conserved both in terms of length and amino acid sequence. Therefore, it is likely to exhibit structural variation. Low-resolution structural data suggest that the *Torpedo* nAChR M3–M4 domain forms a 'hanging basket' type structure connecting the pore with the cytoplasm (Miyazawa et al., 1999). This structure incorporates a lateral ion permeation pathway (or portal) linking the cytoplasm with the inner vestibule at the base of

the pore. Charged residues lining these portals influence the single channel conductance of nAChRs, GlyRs and 5HT$_3$Rs (Peters et al., 2010). Interactions between the M3–M4 loop and other proteins or ions are well known to modulate pLGIC activity, assembly and trafficking (e.g., Luscher et al., 2011). These interactions are highly specific to different pLGIC subunits. The M3–M4 domain is also the only pLGIC region known to house phosphorylation sites.

2.3. Receptor phosphorylation: structural changes induced by kinases?

Phosphorylation results from the kinase-mediated covalent attachment of the γ-phosphate group of ATP to the hydroxyl group of serine, threonine or tyrosine (Fig. 1D). The best-characterized protein kinases include cAMP dependent protein kinase A (PKA), protein kinase C (PKC) and protein tyrosine kinase (PTK). Of these, PKA and PKC phosphorylate both Ser and Thr residues and PTK (including Src family kinase) phosphorylates Tyr residues. Many other kinases also exist such as Ca^{2+}/calmodulin-dependent

Fig. 1. Structure and phosphorylation of pLGICs. (A) Side view of pentameric α3 GlyR homology model viewed parallel to the membrane showing five identical subunits, each colored differently. The large M3–M4 cytoplasmic loop is shown as a dashed line as its structure is not known. (B) Top down view of the same pentameric assembly showing the central pore and the (+) and (−) subunit interfaces. (C) Close-up side view of an extracellular domain subunit interface showing ligand-binding loops A, B and C on the (+) side of the subunit interface and loops D, E and F on the (−) side of the interface. (D) Ion channel phosphorylation pathway. (i) Phosphorylation starts with the binding of ATP to the catalytic site of the protein kinase. (ii) Binding of ATP is followed by protein kinase binding to the substrate receptor. (iii) Followed by γ-phosphate transfer from ATP to Ser/Thr or Tyr of the receptor phosphorylation site. (iv) Following phosphorylation, kinase leaves the receptor with ADP bound, following which ADP is released. (E) Phosphorylation of pLGICs leads to many possible outcomes, some of which are indicated.

protein kinases (CaMKII) which also phosphorylate both Ser and Thr residues (Swope et al., 1999; Davis et al., 2001). The consensus phosphorylation site for Ser/Thr or Tyr specificity is determined by the structure of the catalytic cleft of the kinase and the local interactions between the kinase cleft and protein phosphorylation site. This binding between the kinase and the receptor protein often provides additional binding interactions, and occasionally, provides allosteric regulation and localization to specific cellular compartments or structures (Ubersax and Ferrell, 2007). Phosphorylation can have many effects on pLGIC function, including alterations in open probability and desensitization, surface expression levels, turnover rate and synaptic targeting (Swope et al., 1999; Davis et al., 2001) (Fig. 1E).

3. Biological function

3.1. Chronic inflammatory pain is mediated by phosphorylation of α3 GlyRs

Perhaps the most direct evidence for phosphorylation-induced structural changes in a pLGIC, and its relationship with a disease, has emerged from studies on the α3 GlyR. This will now be described in detail. Inflammatory pain is mediated by the production of prostaglandins in the spinal cord. Electrophysiological studies have identified prostaglandin E_2 (PGE_2) as the most active prostaglandin in the spinal cord, where it specifically inhibits glycinergic inhibitory postsynaptic currents (IPSCs) in lamina I and

Fig. 2. Phosphorylation-mediated conformational changes in the α3 GlyR expressed in *Xenopus laevis* oocytes. (A) Cartoon depicting location of labelled residues for VCF in the ligand-binding site (N203C; green), M2–M3 linker (R19′C; blue) and the phosphorylation site (S346G, magenta). (B) Example of EC_{50} glycine-induced current (ΔI) and fluorescence (ΔF) responses in fluorescently-labelled α3-R19′C and α3-R19′C-S346G GlyRs before and after a 15 min forskolin (FSK) treatment and after a 15 min wash. Averaged results (right panel) reveal that forskolin inhibits glycine-mediated fluorescence responses only in α3 GlyRs containing a functional S346 phosphorylation site. (C) Example and averaged data of saturating glycine- and strychnine-induced ΔI and ΔF responses in fluorescently-labelled α3-N203C and α3-N203C-S346G GlyRs before and after a 15 min forskolin treatment and after a 15 min wash. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Figure modified from Han et al. (2013).

II nociceptive neurons (Ahmadi et al., 2002). This effect is mediated via the activation of the EP_2 receptor and involves the activation of PKA. Although α3 GlyRs are generally sparsely expressed, they are highly expressed along with α1 subunits at glycinergic synapses in lamina I and II neurons (Harvey et al., 2004). As only α3 GlyRs are inhibited by PGE_2 via PKA-dependent phosphorylation at S346 in the M3–M4 domain, it was hypothesised that the α3 subunit was modulated by PGE_2 (Harvey et al., 2004). Although GlyR α3$^{-/-}$ mice displayed no overt behavioural phenotype, normal and knockout mice responded similarly to non-painful tactile stimuli and acute inflammatory pain stimuli. However, chronic inflammation produced pain sensitisation in normal animals but not in the GlyR α3$^{-/-}$ animals (Harvey et al., 2004). Thus, PGE_2 induces chronic pain by phosphorylating, and inhibiting, α3 GlyRs. This reduces the magnitude of glycinergic IPSCs in spinal pain sensory neurons, thereby 'disinhibits' them and increasing the likelihood of pain impulses being transmitted to the brain. Thus, drugs that potentiate (i.e., restore) α3 GlyR IPSCs should be analgesic. Indeed, α3 GlyR-potentiating agents do exert potent analgesic effects in animal pain models. For example, synthetic cannabinoid derivatives modified to prevent their binding to CB1 or CB2 cannabinoid receptors exert potent analgesia via direct effects on α1GlyRs (Xiong et al., 2012).

Phosphorylation-induced conformational changes in the α3 GlyR have recently been probed using voltage clamp fluorometry (VCF) (Han et al., 2013). VCF takes advantage of the fact that changes in the quantum efficiency of small molecule fluorophores occur in response to changes in their chemical microenvironment. It involves introducing a cysteine into the domain of interest and covalently tagging it with a sulfhydryl-labeled fluorophore, often a rhodamine derivative. This technique enables one to probe conformational changes in protein domains of interest in real time. Using

this approach, forskolin-induced PKA phosphorylation of Ser346 in the α3 GlyR cytoplasmic domain elicited a change in the glycine-induced fluorescence response of a label attached to R19′C in the M2–M3 linker or to N203C in loop C of the glycine-binding site (Fig. 2A). This effect was not observed if Ser346 was mutated to prevent its phosphorylation (Fig. 2B and C). Thus, phosphorylation exerts a global conformational change that propagates from S346 in the internal M3–M4 domain to the α1 glycine-binding site, a distance of >80 Å. The experiments shown in Fig. 2 were performed in *Xenopus* oocytes where phosphorylation does not reduce α3 GlyR current. However, when the same receptors are expressed in HEK293 cells, phosphorylation reduced current magnitude and produced a conformational change in the glycine-binding site (Han et al., 2013). This conformational change appears to be unique because it is accompanied by an increase in both glycine sensitivity and the potency of the competitive antagonist, tropisetron (Han et al., 2013). These results raise the possibility of developing analgesic drugs to specifically target disease-affected receptors.

3.2. Phosphorylation-mediated conformational and functional changes in other pLGICs

Phosphorylation also appears to induce conformational changes in $GABA_A$Rs. For example, PKC activators altered the efficacy of benzodiazepines and barbiturates in neuronal $GABA_A$Rs (Gao and Greenfield, 2005). Another study reported that PKC activation reduced the amplitude of GABAergic IPSCs in a manner that was completely inhibited by pre-treatment with neurosteroids (Brussaard et al., 2000). Other studies suggest different PKC isoforms differentially affect $GABA_A$R alcohol sensitivity (Song and Messing, 2005; Qi et al., 2007). Importantly, these later effects have

been implicated in alcoholism. Several other examples of GABA$_A$R subunit phosphorylation sites that have been linked to receptor functional changes and neurological disease are summarized in Table 1.

Many neuronal nAChRs are also regulated by phosphorylation. For example, dephosphorylation of α7 nAChRs caused a rapid increase in acetylcholine-evoked current and alterations in α-bungarotoxin sites with no change in receptor surface expression (Wiesner and Fuhrer, 2006).

Widely expressed in the brain, the α4β2 nAChRs are proposed to play a major role in the mechanisms that cause nicotine addiction. Another study reported that PKA phosphorylation at Ser467 in the M3–M4 domain increases the relative abundance of α4 available for assembly, which favoured the functional expression of low affinity α4β2 receptors (Bermudez and Moroni, 2006). In addition, previous studies had shown the possible functional significance of phosphorylation/dephosphorylation on α4β2 receptor desensitization at the Ser368 residue. Phosphorylation-mediated time course recovery from desensitization implicated different receptor conformations with continuous nicotine exposure leading to an irreversible desensitized conformation (reviewed in Quick and Lester, 2002). Recently, a study by Pollock and colleagues reported a dual effect of PKC at multiple sites of α4 subunits associated with mature and immature receptors. Nicotine has been implicated as a chaperone to promote subunit assembly and stabilize the α4β2 receptors at the cell surface (Pollock et al., 2009). Other examples of neuronal nAChR subunit phosphorylation sites that have been linked to receptor functional changes and neurological disease (notably nicotine addiction and cognitive impairment) are summarized in Table 1.

Muscle nAChRs have also been demonstrated as phosphorylation targets. PKA phosphorylates γ and δ subunits, PKC phosphorylates δ and α subunits and PTK phosphorylates β, γ and δ subunits (Swope et al., 1999). Phosphorylation of muscle nAChRs is related mainly to myasthenia gravis (Table 1).

4. Possible medical applications

Here we demonstrate that neurological disorders can result from conformational changes induced by the 'inappropriate' phosphorylation of pLGICs. For example, PKA-mediated phosphorylation α3 GlyRs (which causes chronic pain) inhibits current and causes a global conformational change that changes the structure of the glycine-binding site (Han et al., 2013), and alcoholism can result from a phosphorylation-induced increase in ethanol sensitivity of γ2-containing GABA$_A$Rs (Qi et al., 2007). We propose that in these and other neurological disorders, phosphorylation induces a global allosteric conformational change that alters the structure of orthosteric or allosteric binding sites.

In classical allosteric theory, receptors are considered to exist in either inactive or active states and drugs that modify their function do so by stabilising one of these states (Nussinov and Tsai, 2014). In reality the situation is much more complex with numerous states existing in unmodified receptors, and even more that can be induced via covalent modifications (such as phosphorylation) or protein–protein interactions. We suggest that an ideal therapeutic drug would bind specifically to a phosphorylated (disease-affected) receptor and promote a conformational change that specifically compensates for the deleterious effect of phosphorylation. As far as we are aware, no such drug has yet been developed for any receptor type. However, there is no reason why this should not be feasible given that phosphorylation is well known to modulate the ability of enzymes to bind specifically to their substrates.

The aim of this brief commentary is to raise awareness of the fact that phosphorylation can cause global allosteric conformational changes in pLGICs and to suggest that these conformations could in principle be targeted by drugs with therapeutic potential.

References

Abramian AM, Comenencia-Ortiz E, Vithlani M, Tretter EV, Sieghart W, Davies PA, et al. Protein kinase C phosphorylation regulates membrane insertion of GABAA receptor subtypes that mediate tonic inhibition. J Biol Chem 2010;285:41795–805.

Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU. PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 2002;5:34–40.

Bermudez I, Moroni M. Phosphorylation and function of alpha4beta2 receptor. J Mol Neurosci 2006;30:97–8.

Brussaard AB, Wossink J, Lodder JC, Kits KS. Progesterone-metabolite prevents protein kinase C-dependent modulation of gamma-aminobutyric acid type A receptors in oxytocin neurons. Proc Natl Acad Sci U S A 2000;97:3625–30.

Charpantier E, Wiesner A, Huh KH, Ogier R, Hoda JC, Allaman G, et al. Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J Neurosci 2005;25:9836–49.

Cho C-H, Song W, Leitzell K, Teo E, Meleth AD, Quick MW, et al. Rapid Upregulation of α7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J Neurosci 2005;25:3712–23.

Davis MJ, Wu X, Nurkiewicz TR, Kawasaki J, Gui P, Hill MA, et al. Regulation of ion channels by protein tyrosine phosphorylation. Am J Physiol 2001;281:H1835–62.

Gao L, Greenfield LJ. Activation of protein kinase C reduces benzodiazepine potency at GABAA receptors in NT2-N neurons. Neuropharmacology 2005;48:333–42.

Guo X, Wecker L. Identification of three cAMP-dependent protein kinase (PKA) phosphorylation sites within the major intracellular domain of neuronal nicotinic receptor alpha4 subunits. J Neurochem 2002;82:439–47.

Han L, Talwar S, Wang Q, Shan Q, Lynch JW. Phosphorylation of alpha3 glycine receptors induces a conformational change in the glycine-binding site. ACS Chem Neurosci 2013;4:1361–70.

Harvey RJ, Depner UB, Wassle H, Ahmadi S, Heindl C, Reinold H, et al. GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 2004;304:884–7.

Hinkle DJ, Macdonald RL. β subunit phosphorylation selectively increases fast desensitization and prolongs deactivation of α1β1(2L and α1β3(2L GABAA receptor currents. J Neurosci 2003;23:11698–710.

Hoffman PW, Ravindran A, Huganir RL. Role of phosphorylation in desensitization of acetylcholine receptors expressed in Xenopus oocytes. J Neurosci 1994;14:4185–95.

Jovanovic JN, Thomas P, Kittler JT, Smart TG, Moss SJ. Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABAA receptor phosphorylation, activity and cell-surface stability. J Neurosci 2004;24:522–30.

Luscher B, Fuchs T, Kilpatrick CL. GABAA receptor trafficking-mediated plasticity of inhibitory synapses. Neuron 2011;70:385–409.

Miyazawa A, Fujiyoshi Y, Stowell M, Unwin N. Nicotinic acetylcholine receptor at 4.6 Å resolution: transverse tunnels in the channel. J Mol Biol 1999;288:765–86.

Nussinov RV, Tsai CJ. Unraveling structural mechanisms of allosteric drug action. Trends Pharmacol Sci 2014;35:256–64.

Peters JA, Cooper MA, Carland JE, Livesey MR, Hales TG, Lambert JJ. Novel structural determinants of single channel conductance and ion selectivity in 5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors. J Physiol 2010;588:587–96.

Pollock VV, Pastoor T, Katnik C, Cuevas J, Wecker L. Cyclic AMP-dependent protein kinase A and protein kinase C phosphorylate alpha4beta2 nicotinic receptor subunits at distinct stages of receptor formation and maturation. Neuroscience 2009;158:1311–25.

Qi Z-H, Song M, Wallace MJ, Newton PM, McMahon T, et al. Protein kinase C epsilon regulates (-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of 2 subunits). J Biol Chem 2007;282:33052–63.

Quick MW, Lester RA. Desensitization of neuronal nicotinic receptors. J Neurobiol 2002;53:457–78.

Rudell JB, Ferns MJ. Regulation of muscle acetylcholine receptor turnover by beta subunit tyrosine phosphorylation. Dev Neurobiol 2013;73:399–410.

Saliba RS, Kretschmannova K, Moss SJ. Activity-dependent phosphorylation of GABAA receptors regulates receptor insertion and tonic current. EMBO J 2012;31:2937–51.

Song M, Messing RO. Protein kinase C regulation of GABAA receptors. Cell Mol Life Sci 2005;62:119–27.

Swope SL, Moss SJ, Raymond LA, Huganir RL. Regulation of ligand-gated ion channels by protein phosphorylation. Adv Second Messenger Phosphoprotein Res 1999;33:49–78.

Terunuma M, Xu J, Vithlani M, Sieghart W, Kittler J, Pangalos M, et al. Deficits in phosphorylation of GABAA receptors by intimately associated protein kinase C activity underlie compromised synaptic inhibition during status epilepticus. J Neurosci 2008;28:376–84.

Tretter V, Revilla-Sanchez R, Houston C, Terunuma M, Havekes R, Florian C, et al. Deficits in spatial memory correlate with modified {gamma}-aminobutyric acid type A receptor tyrosine phosphorylation in the hippocampus. Proc Natl Acad Sci U S A 2009;106:20039–44.

Tzartos SJ, Valcana C, Kouvatsou R, Kokla A. The tyrosine phosphorylation site of the acetylcholine receptor beta subunit is located in a highly immunogenic epitope implicated in channel function: antibody probes for beta subunit phosphorylation and function. EMBO J 1993;12:5141–9.

Ubersax JA, Ferrell JE Jr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 2007;8:530–41.

Wagner K, Edson K, Heginbotham L, Post M, Huganir RL, Czernik AJ. Determination of the tyrosine phosphorylation sites of the nicotinic acetylcholine receptor. J Biol Chem 1991;266:23784–9.

Wecker L, Guo X, Rycerz AM, Edwards SC. Cyclic AMP-dependent protein kinase (PKA) and protein kinase C phosphorylate sites in the amino acid sequence corresponding to the M3/M4 cytoplasmic domain of alpha4 neuronal nicotinic receptor subunits. J Neurochem 2001;76:711–20.

Wiesner A, Fuhrer C. Regulation of nicotinic acetylcholine receptors by tyrosine kinases in the peripheral and central nervous system: same players different roles. Cell Mol Life Sci 2006;63:2818–28.

Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors. J Exp Med 2012;209:1121–34.